Apatinib in Patients with Relapsed or Refractory Diffuse Large B Cell Lymphoma: A Phase II, Open-Label, Single-Arm, Prospective Study

PURPOSE: Treatment options for relapsed or refractory diffuse large B-cell lymphoma (RR DLBCL) represent an unmet medical need. Apatinib is a new oral tyrosine kinase inhibitor mainly targeting vascular endothelial growth factor receptor-2 (VEGFR-2) to inhibit tumour angiogenesis. In the present stu...

Descripción completa

Detalles Bibliográficos
Autores principales: Ma, Xinran, Li, Ling, Zhang, Lei, Fu, Xiaorui, Li, Xin, Wang, Xinhua, Wu, Jingjing, Sun, Zhenchang, Zhang, Xudong, Feng, Xiaoyan, Chang, Yu, Zhou, Zhiyuan, Nan, Feifei, Zhang, Jieming, Li, Zhaoming, Zhang, Mingzhi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2020
Materias:
Clinical Trial Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6986930/
https://www.ncbi.nlm.nih.gov/pubmed/32158186
http://dx.doi.org/10.2147/DDDT.S227477

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6986930/
https://www.ncbi.nlm.nih.gov/pubmed/32158186
http://dx.doi.org/10.2147/DDDT.S227477

Ejemplares similares